# A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

> **NCT00390650** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 366 (actual)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Saredutant

## Key facts

- **NCT ID:** NCT00390650
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2011-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390650, "A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00390650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*